OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.
|Videos|September 14, 2021
Dr. Ehdaie weighs in on focal therapy with MRgFUS for GG2/3 prostate cancer
Author(s)Urology Times staff
Advertisement
In this video, Behfar Ehdaie, MD, MPH, compared magnetic resonance (MR)–guided focused ultrasound (MRgFUS) with other forms of focal therapy used to treat prostate cancer as well as the learning curve associated with this specific therapy.
During the 2021 AUA Annual Meeting, Ehdaie
Ehdaie is an assistant member of the urology service department of surgery at Memorial Sloan Kettering Cancer Center, New York City, New York.
Advertisement
Related to this article
Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Advertisement
Advertisement